Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Autor: Cheng, Ann-Lii, Qin, Shukui, Ikeda, Masafumi, Galle, Peter R., Ducreux, Michel, Kim, Tae-You, Lim, Ho Yeong, Kudo, Masatoshi, Breder, Valeriy, Merle, Philippe, Kaseb, Ahmed O., Li, Daneng, Verret, Wendy, Ma, Ning, Nicholas, Alan, Wang, Yifan, Li, Lindong, Zhu, Andrew X., Finn, Richard S.
Zdroj: In Journal of Hepatology April 2022 76(4):862-873
Databáze: ScienceDirect
Externí odkaz: